Inhibitors of kinases

Details Inhibitors of kinases Inhibitors of kinases

2009-03-06

2010-10-26

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S243000

Reexamination Certificate

active

07820814

ABSTRACT:
The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

REFERENCES:
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 6933386 (2005-08-01), Bhide et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 6969717 (2005-11-01), Bhide et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 7030118 (2006-04-01), Lombardo et al.
patent: 7034151 (2006-04-01), Chen et al.
patent: 7112675 (2006-09-01), Hunt et al.
patent: 7211666 (2007-05-01), Godfrey, Jr. et al.
patent: 7244733 (2007-07-01), Hunt et al.
patent: 7265113 (2007-09-01), Bhide et al.
patent: 7521450 (2009-04-01), Bhide et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: WO 00/71129 (2000-11-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 2004/009542 (2004-01-01), None
Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer et al., Bio/Technology, 1994, 12:320.
Cohen et al., Current Opinion in Chemical Biology, 3,459-465, 1999.
Golub et al., Science, 286, 531-537, 1999.
Fan et al., Trend Pharcol. Sci., vol. 16, pp. 57-66 (1995).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrinology, vol. 133, pp. 848-859 (1993).
Kolch et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part1”, 1995, pp. 975-977.
Banker, G.S. et al., “Modern Pharmaceuticals, 3ed.”, 1996, pp. 451 and 596.
West, Anthony R., “Solid State Chemistry and its Applications”, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, pp. 3-26, 2001.
Cecil Textbook of Medicine, vol. 1, pp. 1004-1010 (1996).
Mass, R.D., Int. J. Radiation Oncology Bio. Phys., vol. 58, No. 3, pp. 932-940 (2004).
Fabbro et al., Pharmacology and Therapeutics, vol. 93, pp. 79-98 (2002).
Eskens, British Journal of Cancer, vol. 90, pp. 1-7 (2004).
Milgliara et al., J. Heterocyclic. Chem., vol. 16, pp. 833-834 (1979).
Patil et al., J. Heterocyclic. Chem., vol. 31, pp. 781-786 (1994).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
List of Results for search of: Brivanib; www.clinicaltrials.gov (Dec. 9, 2009).
“Angiogenesis and Vascular Endothelial Growth Factor (VEGF)”; slide kit provided by ResearchVEGF.com.

Affiliated with

Also associated with

Rating

Inhibitors of kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4160981